These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 35467476

  • 1. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
    Zitzmann M, Cremers JF, Krallmann C, Kliesch S.
    Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
    [Abstract] [Full Text] [Related]

  • 2. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M, Nieschlag E.
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [Abstract] [Full Text] [Related]

  • 3. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T, Schubert M, Freude S, Hübler D, Gouni-Berthold I, Schumann C, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F.
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [Abstract] [Full Text] [Related]

  • 4. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S, Khupulsup K, Leelaphiwat S, Pavavattananusorn S, Thongpradit S, Petchthong T.
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [Abstract] [Full Text] [Related]

  • 5. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ.
    J Androl; 1998 Aug; 19(6):761-8. PubMed ID: 9876028
    [Abstract] [Full Text] [Related]

  • 6. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F.
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [Abstract] [Full Text] [Related]

  • 7. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA, Triggiani V, Carbone MD, Corona G, Tafaro E, Licchelli B, Guastamacchia E.
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
    Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A.
    J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
    [Abstract] [Full Text] [Related]

  • 9. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M.
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [Abstract] [Full Text] [Related]

  • 10. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
    Yassin DJ, Doros G, Hammerer PG, Yassin AA.
    J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
    [Abstract] [Full Text] [Related]

  • 11. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
    Jockenhövel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Müller-Wieland D, Krone W.
    Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C, Harnett M, Dobs AS, Swerdloff RS.
    J Androl; 2010 May; 31(5):457-65. PubMed ID: 20133964
    [Abstract] [Full Text] [Related]

  • 13. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
    Honig S, Gittelman M, Kaminetsky J, Wang C, Amory JK, Rohowsky N, Dudley RE, Woun Seo B, Newmark J, Swerdloff R.
    J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
    [Abstract] [Full Text] [Related]

  • 14. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
    Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E.
    Eur J Endocrinol; 1999 May; 140(5):414-9. PubMed ID: 10229906
    [Abstract] [Full Text] [Related]

  • 15. Effects of various modes of androgen substitution therapy on erythropoiesis.
    Jockenhövel F, Vogel E, Reinhardt W, Reinwein D.
    Eur J Med Res; 1997 Jul 28; 2(7):293-8. PubMed ID: 9233903
    [Abstract] [Full Text] [Related]

  • 16. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study.
    Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E.
    J Clin Endocrinol Metab; 2003 May 28; 88(5):2049-54. PubMed ID: 12727953
    [Abstract] [Full Text] [Related]

  • 17. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy.
    Dimitriadis GK, Randeva HS, Aftab S, Ali A, Hattersley JG, Pandey S, Grammatopoulos DK, Valsamakis G, Mastorakos G, Jones TH, Barber TM.
    Endocrine; 2018 Apr 28; 60(1):175-184. PubMed ID: 29396841
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
    Jockenhövel F, Minnemann T, Schubert M, Freude S, Hübler D, Schumann C, Christoph A, Ernst M.
    Eur J Endocrinol; 2009 May 28; 160(5):815-9. PubMed ID: 19225035
    [Abstract] [Full Text] [Related]

  • 20. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men.
    Nieschlag E, Büchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM.
    Clin Endocrinol (Oxf); 1999 Dec 28; 51(6):757-63. PubMed ID: 10619981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.